Literature DB >> 7569016

EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system.

P Rubin, L S Constine, L F Fajardo, T L Phillips, T H Wasserman.   

Abstract

Mesh：

Year:  1995        PMID： 7569016     DOI： 10.1016/0167-8140(95)97447-l

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


× No keyword cloud information.
  16 in total

1.  The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome.

Authors:  Andrew Jackson; Lawrence B Marks; Søren M Bentzen; Avraham Eisbruch; Ellen D Yorke; Randal K Ten Haken; Louis S Constine; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  Follow-up care for young adult survivors of cancer: lessons from pediatrics.

Authors:  Christine Eiser; Kate Absolom; Diana Greenfield; John Snowden; Robert Coleman; Barry Hancock; Helena Davies
Journal:  J Cancer Surviv       Date:  2007-03       Impact factor: 4.442

3.  Parotid sparing and quality of life in long-term survivors of locally advanced head and neck cancer after intensity-modulated radiation therapy.

Authors:  Silke Tribius; Sven Haladyn; Henning Hanken; Chia-Jung Busch; Andreas Krüll; Cordula Petersen; Corinna Bergelt
Journal:  Strahlenther Onkol       Date:  2020-12-30       Impact factor: 3.621

4.  Phase I study of continuous mitomycin-C infusion in concomitant radiochemotherapy of primary inoperable advanced head and neck cancer.

Authors:  Hans Christiansen; Robert M Hermann; Andrea Hille; Heinz Schmidberger; Alexios Martin; Mirko Nitsche; Clemens F Hess; Olivier Pradier
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-15       Impact factor: 4.553

5.  Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer.

Authors:  Hendrik A Wolff; Lena-Christin Conradi; Markus Schirmer; Tim Beissbarth; Thilo Sprenger; Margret Rave-Fränk; Steffen Hennies; Clemens F Hess; Heinz Becker; Hans Christiansen; Torsten Liersch
Journal:  Oncologist       Date:  2011-05-09

6.  A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy.

Authors:  F A Olopade; A Norman; P Blake; D P Dearnaley; K J Harrington; V Khoo; D Tait; C Hackett; H J N Andreyev
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

7.  A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes.

Authors:  A B Miah; U Schick; S A Bhide; M-T Guerrero-Urbano; C H Clark; A M Bidmead; S Bodla; L Del Rosario; K Thway; P Wilson; K L Newbold; K J Harrington; C M Nutting
Journal:  Br J Cancer       Date:  2014-12-04       Impact factor: 7.640

8.  Experience with intraoperative radiotherapy for breast cancer: the Geneva University Hospital's experience.

Authors:  Emanuela Esposito; Michae Douek
Journal:  Chin J Cancer Res       Date:  2016-08       Impact factor: 5.087

9.  Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas.

Authors:  Hendrik Andreas Wolff; Ralph M W Rödel; Bastian Gunawan; Tobias Overbeck; Markus K A Herrmann; Steffen Hennies; Andrea Hille; Hilke Vorwerk; Christoph Matthias; Clemens F Hess; Hans Christiansen
Journal:  J Cancer Res Clin Oncol       Date:  2009-07-18       Impact factor: 4.553

10.  Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer.

Authors:  Hendrik Andreas Wolff; Tobias Overbeck; Ralph M Roedel; Robert M Hermann; Markus K A Herrmann; Tereza Kertesz; Hilke Vorwerk; Andrea Hille; Christoph Matthias; Clemens F Hess; Hans Christiansen
Journal:  J Cancer Res Clin Oncol       Date:  2008-12-24       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.